ASsessment of Platelet function in patients Recovering from severe INfection

Vrije Universiteit Medisch Centrum Amsterdam0 个研究点目标入组 97 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in the main-trial, a subject must meet all of the following criteria:
•Primary clinical diagnosis of pneumonia
•Primary clinical diagnosis of invasive urinary tract infection
•Primary clinical diagnosis of cutaneous infection
•18 years or older on the date of hospital presentation
•Hospitalization for at least 24 hours
•Having received at least 1 dose of antibiotics within 48 hours of admission.
•In order to be eligible to participate in the sub-study, a subject must meet all of the following criteria:
•Primary clinical diagnosis of pneumonia
•Primary clinical diagnosis of invasive urinary tract infection
•Primary clinical diagnosis of cutaneous infection
•18 years or older on the date of hospital presentation
•Hospitalization for at least 24 hours
•Having received at least 1 dose of antibiotics within 48 hours of admission
•Known stable cardiovascular disease. Stable cardiovascular disease defined as: coronary artery disease, peripheral vascular disease, or previous myocardial infarction (>12 months).
•Chronic usage of 80 mg of non-enteric coated acetylsalicylic acid once daily in the

•A potential subject who meets any of the following criteria will be excluded from participation in the main-trial:
•-Active metastatic cancer (c.q. malignancy)
•-Allergy to salicylate
•-Platelet count <120*109/l
•-History of non-traumatic major bleeding
•-Known bleeding diathesis
•-Conditions which require antiplatelet therapy
•-Usage of antiplatelet therapy
•-Surgery 1 month prior to diagnosis
•-Currently pregnant
•-Chronic usage of medication which are known to influence
•platelet function other than antibiotics (e.g. NSAID’s, tirofiban, eptifibatide, abciximab, SSRI’s, clomipramine, amitriptyline, dipyridamole, verapamil, diltiazem , ginkgo biloba, ginseng, & St John’s wort)
•A potential subject who meets any of the following criteria will be excluded from participation in the sub-study:
•-Active metastatic cancer (c.q. malignancy)
•-Platelet count <120*109/l
•-History of non-traumatic major bleeding
•-Known bleeding diathesis
•-Surgery 1 month prior to diagnosis
•-Currently pregnant
•-Cardiovascular event < 12 months prior
•-Chronic usage of medication which are known to influence
•platelet function other than antibiotics or aspirin (e.g. NSAID’s, tirofiban, eptifibatide, abciximab, SSRI’s, clomipramine, amitriptyline, dipyridamole, verapamil, diltiazem , ginkgo biloba, ginseng, & St John’s wort)

发起方

Vrije Universiteit Medisch Centrum Amsterdam